The APEX1 Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout population of A-549 human lung adenocarcinoma cells with disruption of the APEX1 gene. This loss-of-function model eliminates APEX1??s dual activities in DNA base excision repair and redox transcriptional regulation. The polyclonal format preserves allelic diversity, avoiding clonal selection bias, and is suitable for pooled functional genomics, mixed-population assays, and studies of heterogeneous knockout effects in cancer cell populations.
The A-549 parental line was derived from a 58-year-old Caucasian male with lung carcinoma and exhibits adherent epithelial morphology. It harbors KRAS and STK11 mutations, making it a widely used model for non-small cell lung cancer with activated KRAS signaling. Its competent DNA damage response and sensitivity to oxidative stress provide a physiologically relevant background for dissecting APEX1 function in lung adenocarcinoma.
APEX1 functions at the interface of genome maintenance and redox signaling. Its endonuclease activity cleaves abasic sites in DNA, initiating base excision repair, and it interacts with DNA polymerase ??, XRCC1, and PARP1. Its redox function reduces cysteine residues in transcription factors such as c-Fos, c-Jun (AP-1), NF-??B p50/p65, HIF-1??, and p53, enhancing their DNA binding. Upstream signals including ROS, CK2, and PKC regulate APEX1, while downstream targets encompass VEGF, BCL2, and MMPs, connecting oxidative input to cell survival and proliferation.
In A-549 cells, APEX1 is often overexpressed and contributes to chemoresistance and redox adaptation. Its knockout impairs repair and redox control, leading to DNA damage accumulation, genomic instability, and dysregulation of AP-1, NF-??B, and p53 target genes. This model enables investigation of synthetic lethal interactions with PARP inhibitors, mechanisms of DNA-damaging drug resistance, and the role of APEX1 in oxidative stress responses.
Typical applications include AP site cleavage and comet assays for repair; luciferase reporters for NF-??B/AP-1 activity; flow cytometry for apoptosis; transwell migration; and clonogenic survival after genotoxic or oxidative challenge. Western blotting, immunofluorescence, and RT-qPCR confirm protein and transcript changes. Combined with RNA-seq, the model supports transcriptome-wide analyses of APEX1-dependent gene networks. Researchers are encouraged to contact Ascent Research for additional technical information and application assistance.
